News 2022

Patients with invasive breast cancer that had low scores on an investigational gene molecular signature had similar rates of local recurrence whether or not they received adjuvant radiation therapy after breast-conserving surgery: December 2022

Using animal modelling and human transcriptomic datasets, Edinburgh researchers demonstrated that FAK-IL6 signalling amplifies pathways associated with immune suppression and poor patient prognosis in pancreatic ductal adenocarcinoma.

A recent study has demonstrated that, contrary to recent reports, the transcriptional output of oncogenes carried on extrachromosomal DNA in glioblastoma stem cells is driven by the copy number of the ecDNA, rather than their spatial localization into transcriptional hubs: December 2022

Radiotherapy after breast conserving surgery in conjunction with chemotherapy or tamoxifen to treat early breast cancer reduces the risk of the disease returning in the same breast in the next ten years but makes little difference to that risk thereafter. Nor does it improve overall survival after 30 years.

Scientists at the Institute of Genetics and Cancer investigating the mechanics of the early stages of lung cancer have identified a new potential treatment, which could also aid early detection of the disease: November 2022

Our Institute’s Cross-Disciplinary Fellowship (XDF) Programme Annual Symposium took place on the 5th of October delivering a feast of cross-disciplinary science

Results of an international study with its UK component led from Edinburgh has led to approval of the first ever treatment reducing relapse after kidney cancer surgery: October 2022

Congratulations to Adelaide Young, Marta Canel, Øyvind Almelid and Jareth Wolfe on recently receiving National Postdoc Appreciation Week Awards for their work at the Institute: September 2022

Edinburgh researchers contributed to a study describing a novel approach for mapping cell states, modelling cell state transitions and predicting targeted interventions to convert cell fate decisions: September 2022

Why are brain tumours so hard to treat? What's it like living with brain cancer and what role does research have in developing our understanding of cancer? In 2022, we shone a light on brain cancer to answer these questions and more.

Our postdoctoral researcher Piotr Manasterski completed a gruelling IRONMAN Tallinn event to raise awareness about the importance of sarcoma research: September 2022

A new fund has been launched by the Institute of Genetics and Cancer to support early career researchers in their journey to independence, thanks to a significant philanthropic donation from Hugh and Josseline Langmuir: September 2022

Women with an early form of breast cancer are more likely to stay free of the disease after an extra radiotherapy boost, new research shows.

Our investigators report detailed clinical and histopathological characterisation of the largest pathologically confirmed cohort of ovarian carcinosarcoma patients to date: August 2022

Edinburgh researchers report a ligand-tetrazine conjugate approach to “track & treat” malignant cells that are capable of evading the immune system: August 2022

Edinburgh researchers used a unique sample set to provide new insights into endocrine therapy resistance in estrogen receptor positive breast cancer: August 2022

Edinburgh researchers show that RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer: August 2022

Edinburgh led study provides high-resolution picture of the molecular landscape in high-grade serous ovarian carcinoma, better defining patients who may benefit most from specific molecular therapeutics and highlighting those for whom novel treatment strategies are needed to improve outcomes: July 2022

A study by Edinburgh scientists provides important new information on the ability of cell adhesion molecules to relocate to the cell nucleus: June 2022

Edinburgh researchers developed an orally bioavailable palladium activated 5-Fluorouracil precursor designed to evade anabolic and catabolic drug pathways: March 2022

Our researchers demonstrated that loss of Integrin-Linked Kinase sensitizes triple negative breast cancer to SRC inhibition: February 2022

Important contributions of Edinburgh investigators to the GOG281/LOGS clinical trial that offers new standard of care option for women with progressive or relapsed low-grade serous ovarian cancer.

The charity has announced that experts in Edinburgh and Glasgow - the Cancer Research UK Scotland Centre - will receive the funding over the next five years for their ground-breaking work as part of a unique chain of cutting-edge research hubs around the UK: February 2022

Virtual Lab Tour with Prof Neil Carragher’s Research Group

The work, led by Alessandro Brombin and Liz Patton and in collaboration with Tamir Chandra, could potentially inform improved drug therapies for people living with melanoma: January 2022

Regional variation in chemotherapy treatment for breast cancer across Scotland has reduced significantly over the past 15 years, according to a new study: December 2021

Professor Tim Aitman received the medal on behalf of the team for significant achievements in pioneering a way to mass population testing in an epidemic: December 2021

Edinburgh clinicians contributed to a study that developed new AI-based predictor of response to cancer therapy: December 2021